Patents matching “SION”

US 2012100163

SUPPRESSION OF A TYPE 1 HYPERSENSITIVITY IMMUNE RESPONSE WITH AN UNRELATED ANTIGEN

BRIMNES JENS [DK] · Granted Apr 26, 2012 · Expires Apr 21, 2032

US 2012100164

SUPPRESSION OF A HYPERSENSITIVITY IMMUNE RESPONSE WITH UNRELATED ANTIGEN DERIVED FROM ALLERGEN SOURCE MATERIAL

BRIMNES JENS [DK] · Granted Apr 26, 2012 · Expires Apr 21, 2032

US 8163711

Compositions and methods for inhibiting expression of the HAMP gene

Alnylam Pharmaceuticals, Inc. · Granted Apr 24, 2012 · Expires Apr 19, 2032

US 8165643

Charging cradle

CHENG UEI PRECISION INDUSTRY CO., LTD. · Granted Apr 24, 2012 · Expires Apr 19, 2032

US 8158596

Materials and methods for FOXP3 tumor suppression

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 17, 2012 · Expires Apr 12, 2032

US 8158581

IGF-1 fusion polypeptides and therapeutic uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Apr 17, 2012 · Expires Apr 12, 2032

US 8158126

Stem cell fusion model of carcinogenesis

Arizona Board of Regents on Behalf of the University of Arizona · Granted Apr 17, 2012 · Expires Apr 12, 2032

US 8143390

Compositions and methods for inhibiting expression of anti-apoptotic genes

Alnylam Pharmaceuticals, Inc. · Granted Mar 27, 2012 · Expires Mar 22, 2032

US 8143232

Gene fusion targeted therapy

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Mar 27, 2012 · Expires Mar 22, 2032

US 8129510

Minigene expression cassette

Benitec Biopharma Limited · Granted Mar 6, 2012 · Expires Mar 1, 2032

US 8128924

Methods for using a three-dimensional stromal tissue to promote angiogenesis

Theregen, Inc. · Granted Mar 6, 2012 · Expires Mar 1, 2032

US 8123541

Electrical connector with expanded cover

Hon Hai Precision Ind. Co., Ltd. · Granted Feb 28, 2012 · Expires Feb 23, 2032

US 8119608

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. · Granted Feb 21, 2012 · Expires Feb 16, 2032

US 8114981

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. · Granted Feb 14, 2012 · Expires Feb 9, 2032

US 8114851

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. · Granted Feb 14, 2012 · Expires Feb 9, 2032

US 8101584

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. · Granted Jan 24, 2012 · Expires Jan 19, 2032

US 8101739

Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector

The United States of America, as represented by the Department of Health and Human Services · Granted Jan 24, 2012 · Expires Jan 19, 2032

US 8101742

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. · Granted Jan 24, 2012 · Expires Jan 19, 2032

US 8101740

Positron emission tomography probes for imaging immune activation and selected cancers

The Regents of the University of California · Granted Jan 24, 2012 · Expires Jan 19, 2032

US 8084599

Methods and compositions for the specific inhibition of gene expression by double-stranded RNA

INTEGRATED DNA TECHNOLOGIES, INC. · Granted Dec 27, 2011 · Expires Dec 22, 2031

US 8084250

Defensin-antigen fusion proteins

The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Dec 27, 2011 · Expires Dec 22, 2031

US 8084234

Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF

REGENERON PHARMACEUTICALS, INC. · Granted Dec 27, 2011 · Expires Dec 22, 2031

US 8080532

Compositions and methods for inhibiting expression of Huntingtin gene

Alnylam Pharmaceuticals, Inc. · Granted Dec 20, 2011 · Expires Dec 15, 2031

US 8080651

Juvenile hemochromatosis gene (HFE2A), expression products and uses thereof

Xenon Pharmaceuticals Inc. · Granted Dec 20, 2011 · Expires Dec 15, 2031